尿酸水平的变化和功能在12个月使用luseogliflozin治疗期间的关系
Takuma Izutsu1,2, Hiroyuki Ito2, Suzuko Matsumoto2
1Department of Diabetes and Endocrinology, Iwate Prefectural Central Hospital, Iwate Prefectural Central Hospital, 1-4-1 Ueda, Moriokasi, Iwate 020-0066 Japan.
Diabetology international
|December 8, 2025
概括
像luseogliflozin这样的-葡萄糖共运输体-2 (SGLT2) 抑制剂可以降低尿酸 (UA) 并改善2型糖尿病的血糖控制. UA减少与功能变化相关,表明UA是健康的标志物.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
背景情况:
- -葡萄糖共运输体-2 (SGLT2) 抑制剂是已确立的2型糖尿病治疗方法,提供超出血糖控制的好处,包括心血管和脏保护.
- 虽然SGLT2抑制剂降低尿酸 (UA) 水平,但在这种情况下,UA减少和功能保存之间的特定关系需要进一步研究.
- 作为SGLT2抑制剂的卢塞奥格利弗洛辛在治疗2型糖尿病方面已被证明是有效的,但其对脏参数的影响,特别是与UA水平相关的影响,需要详细评估.
研究的目的:
- 评估luseogliflozin对2型糖尿病患者尿酸 (UA) 水平,代谢参数和功能的影响.
- 为了研究UA减少和估计的膜过率 (eGFR) 变化后 luseogliflozin治疗之间的相关性.
- 探索UA降低作为2型糖尿病管理中脏保护策略的替代标记物的潜力.
主要方法:
- 一项回顾性研究涉及353名2型糖尿病患者,这些患者最近接受了 luseogliflozin 的治疗.
- 根据基线UA水平,患者被分为两组:低 (<6.0 mg/dL) 和高 (≥6.0 mg/dL).
- 在12个月的时间内,对UA,糖化血红蛋白 (HbA1c) 和eGFR的变化进行了监测.
主要成果:
- 两组在12个月的luseogliflozin治疗后,UA和HbA1c显著降低.
- 在低UA组中观察到EGFR显著下降 (-3.1mL/min/1.73m2),而在高UA组中没有显著变化 (-0.8mL/min/1.73m2).
- 在高UA组中观察到更大的UA减少,UA变化与eGFR变化有显著的相关性 (p=0.008),但与HbA1c变化没有相关性.
结论:
- 卢塞奥格利弗洛辛治疗导致UA和HbA1c在2型糖尿病患者中的显著降低.
- 格利弗洛辛对功能 (eGFR) 的影响受基线UA水平的影响,在基线UA较低的患者中观察到显著下降.
- 在SGLT2抑制剂治疗期间UA水平的变化可以作为反映代谢过程的替代标记,并与血压和白尿等参数相关.
相关概念视频
Factors Affecting Renal Clearance: Renal Impairment
402
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
402
Renal Failure: Dose Adjustments
407
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
407
Acute Kidney Injury III: Clinical Manifestations
778
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
778
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
196
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
196
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
174
Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
174
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
221
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
221


